Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET1402L1-ARTEMIS T-cells in AFP+ HCC
NCT03888859Phase 1Completed
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2017
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of et1402l1-artemis t cells in hepatocellular carcinoma (HCC) (3 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Dose-Limiting Toxicity at 2 years and Adverse Events at 2 years. Started Dec 2017; status: completed.
02
Drugs
et1402l1-artemis t cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03888859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888859.